Compare Crispr Therapeutics AG (CRSP) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Walmart Stores Inc — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Walmart Stores Inc trades at $113.86 (market cap $904.83B). The key difference: Walmart Stores Inc is far larger — about 182.1× Crispr Therapeutics AG's market cap, and Walmart Stores Inc pays a 0.87% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WMT | |
|---|---|---|
Market Cap | $4.97B | $904.83B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $134.20 |
52-Week Low | $44.34 | $95.05 |
Enterprise Value | $3.32B | $968.28B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Walmart (WMT) trades at $114.78, up 0.77% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $681.0B in 2025 and a rising net income margin of 2.85%. Analyst consensus is strongly bullish with a $142.10 price target, though technical indicators show resistance near $115. Recent news highlights operational expansions in drone delivery and AI tools, alongside competitive pressures as Amazon overtakes it on the Fortune 500.
The outlook for WMT is positive based on fundamental strength and analyst optimism, but near-term technical resistance and competitive risks warrant caution. Investment opportunity lies in its consistent earnings performance and dividend yield, while risks include market volatility and execution challenges in e-commerce growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
